News & Media

Boehringer Ingelheim News, Press Releases & Information

Quick access to the latest company news, including corporate, research & development and human pharmaceuticals for members of the media.

Press Release Subscription

Please submit the form below to receive press releases via email.

Information for...

PRESS RELEASE 13 Dec 2018 at 06:30

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Read more on Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
- Press Release
PRESS RELEASE 26 Nov 2018 at 14:00

Jardiance^{^®} Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Read more on
Jardiance^{^®} Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
PRESS RELEASE 15 Nov 2018 at 06:30

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Read more on Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
PRESS RELEASE 05 Nov 2018 at 06:30

Initial results from EMPRISE real-world evidence study show Jardiance^{^®} was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Read more on
Initial results from EMPRISE real-world evidence study show Jardiance^{^®} was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
PRESS RELEASE 31 Oct 2018 at 11:00

Boehringer Ingelheim Announces Growth in the Bay Area

Read more on Boehringer Ingelheim Announces Growth in the Bay Area
- Press Release
PRESS RELEASE 22 Oct 2018 at 09:00

Real-world study shows sequencing of Gilotrif^{^®} followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Read more on
Real-world study shows sequencing of Gilotrif^{^®} followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC
PRESS RELEASE 11 Oct 2018 at 08:00

FDA Approves Stiolto^{^®} Respimat^{^®} Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Read more on
FDA Approves Stiolto^{^®} Respimat^{^®} Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
PRESS RELEASE 10 Oct 2018 at 08:00

New Internal Teat Sealant Added to Boehringer Ingelheim Dairy Mastitis Portfolio

Read more on New Internal Teat Sealant Added to Boehringer Ingelheim Dairy Mastitis Portfolio
PRESS RELEASE 10 Oct 2018 at 06:30

New analysis estimates the positive impact of Jardiance^{^®} on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Read more on
New analysis estimates the positive impact of Jardiance^{^®} on life expectancy in adults with type 2 diabetes and established cardiovascular disease
PRESS RELEASE 04 Oct 2018 at 11:15

Boehringer Ingelheim and Lilly present full results of Tradjenta^{^®}’s CARMELINA^{^®} cardiovascular outcome trial

Read more on
Boehringer Ingelheim and Lilly present full results of Tradjenta^{^®}’s CARMELINA^{^®} cardiovascular outcome trial
- Press Release
PRESS RELEASE 04 Oct 2018 at 06:30

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

Read more on Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
- Press Release
PRESS RELEASE 02 Oct 2018 at 08:00

Introducing SEMINTRA® (telmisartan oral solution) —The First FDA-Approved Liquid Solution For Feline Hypertension

Read more on Introducing SEMINTRA® (telmisartan oral solution) —The First FDA-Approved Liquid Solution For Feline Hypertension
PRESS RELEASE 26 Sep 2018 at 09:00

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC

Read more on Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
PRESS RELEASE 25 Sep 2018 at 09:15

Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)

Read more on
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)
PRESS RELEASE 17 Sep 2018 at 08:00

New study results provide evidence that Ofev^{^®} (nintedanib) slows progression of IPF beyond four years with consistent safety

Read more on
New study results provide evidence that Ofev^{^®} (nintedanib) slows progression of IPF beyond four years with consistent safety
- Press Release
PRESS RELEASE 13 Sep 2018 at 02:00

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Read more on Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
PRESS RELEASE 12 Sep 2018 at 08:00

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

Read more on Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
PRESS RELEASE 12 Sep 2018 at 08:00

Boehringer Ingelheim to Donate 75,000 Doses of Rabies Vaccine to the Global Alliance for Rabies Control Through Shots for Good Initiative

Read more on Boehringer Ingelheim to Donate 75,000 Doses of Rabies Vaccine to the Global Alliance for Rabies Control Through Shots for Good Initiative
PRESS RELEASE 07 Sep 2018 at 08:00

What You Should Know About Coliform Mastitis

Read more on What You Should Know About Coliform Mastitis
PRESS RELEASE 05 Sep 2018 at 08:00

Researchers focused on infectious respiratory disease in pigs may apply for Boehringer Ingelheim research awards

Read more on Researchers focused on infectious respiratory disease in pigs may apply for Boehringer Ingelheim research awards

Search form

News & Media

Boehringer Ingelheim News, Press Releases & Information

Press Release Subscription